PROCEPT BioRobotics Corporation $PRCT Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC boosted its stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 142.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,294 shares of the company’s stock after purchasing an additional 49,457 shares during the period. SG Americas Securities LLC owned approximately 0.15% of PROCEPT BioRobotics worth $2,652,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Diversified Trust Co. lifted its stake in shares of PROCEPT BioRobotics by 88.8% during the fourth quarter. Diversified Trust Co. now owns 30,634 shares of the company’s stock worth $964,000 after purchasing an additional 14,408 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of PROCEPT BioRobotics by 24.0% during the 3rd quarter. IFP Advisors Inc now owns 5,024 shares of the company’s stock valued at $179,000 after buying an additional 974 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in shares of PROCEPT BioRobotics during the 3rd quarter valued at about $227,000. Voleon Capital Management LP acquired a new position in PROCEPT BioRobotics during the 3rd quarter worth approximately $236,000. Finally, Verition Fund Management LLC lifted its position in PROCEPT BioRobotics by 76.7% during the 3rd quarter. Verition Fund Management LLC now owns 61,793 shares of the company’s stock worth $2,205,000 after acquiring an additional 26,815 shares in the last quarter. 89.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at PROCEPT BioRobotics

In related news, EVP Kevin Waters sold 6,721 shares of the stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $23.70, for a total value of $159,287.70. Following the sale, the executive vice president owned 152,264 shares of the company’s stock, valued at $3,608,656.80. This trade represents a 4.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Alaleh Nouri sold 6,892 shares of PROCEPT BioRobotics stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $23.70, for a total transaction of $163,340.40. Following the completion of the sale, the executive vice president owned 114,264 shares in the company, valued at approximately $2,708,056.80. This represents a 5.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders bought 426,262 shares of company stock worth $10,483,091 and sold 23,229 shares worth $573,466. Insiders own 6.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on PRCT shares. Robert W. Baird initiated coverage on shares of PROCEPT BioRobotics in a research report on Friday, March 6th. They issued a “neutral” rating and a $30.00 price objective for the company. Oppenheimer reissued a “market perform” rating on shares of PROCEPT BioRobotics in a research report on Thursday, February 26th. Bank of America lowered PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and cut their target price for the company from $38.00 to $20.00 in a research report on Thursday, February 26th. TD Cowen decreased their price target on shares of PROCEPT BioRobotics from $50.00 to $34.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Finally, Wall Street Zen lowered shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $40.82.

PROCEPT BioRobotics Price Performance

Shares of PROCEPT BioRobotics stock opened at $25.12 on Friday. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -14.69 and a beta of 0.94. PROCEPT BioRobotics Corporation has a twelve month low of $19.35 and a twelve month high of $66.85. The company has a current ratio of 6.85, a quick ratio of 5.77 and a debt-to-equity ratio of 0.14. The business’s 50 day simple moving average is $26.95 and its 200-day simple moving average is $31.15.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. The company had revenue of $76.38 million for the quarter, compared to analyst estimates of $93.70 million. During the same quarter in the prior year, the firm earned ($0.35) EPS. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. Equities research analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.